Navigation Links
PRA International Hosts Audio Conference on CV Drug Development
Date:8/16/2010

RALEIGH, N.C., Aug. 16 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

Dr. Kirchengast will discuss ways to prevent some of the expensive failures that pharmaceutical companies experience during late-stage CV drug development. The conference will review predictive pre-clinical models, innovative proof-of-concept designs in Phase IIa, cooperation among sponsors and regulatory agencies, and simpler protocols with similar endpoints throughout Phases II and III.

PRA's therapeutic expert in CV disease, Dr. Kirchengast has 30 years of experience in CV research and development, including interactions with multiple authorities. His wide range of development experience encompasses antiarrhythmics, antithrombotics, antihypertensives, antihyperlipidemics, heart failure therapeutics, and vascularly active and cardioprotective drugs.

PRA's Scientific Affairs group consists of strategic drug development professionals with expertise in medical informatics and investigator relations as well as therapeutic expertise in cardiovascular, oncology/hematology, infectious diseases, neurosciences, pediatrics, and respiratory medicine. The group combines in-house scientific expertise with hands-on pharmaceutical industry experience, guiding the development of drugs and biologics from the late preclinical phase to the marketing stage across PRA's core therapeutic areas.

For more information about this audio conference, navigate to www.praintl.com and click on "Events." To register, email endpoints@praintl.com. The registration deadline is Monday, 23 August 2010.

About PRA International

PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 38 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dyadic International Reports 2010 Second Quarter Financial Results
2. Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010
3. Chindex International to Report First Quarter 2011 Financial Results
4. Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International
5. Airline Passenger Experience Association Teams Up With ORBIS International in Their Fight Against Avoidable Blindness
6. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
7. New Edition of Guidelines for Involving Communities in HIV Prevention Research Released at International AIDS Conference
8. SRI International and Stanford University School of Medicines MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices
9. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
10. Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimers Disease at International Conference on Alzheimers Disease (ICAD)
11. PRA International Hosts Audio Conference on Site and Patient Recruitment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 To mark the ... , Inc., a leader in digital imaging solutions, will ... East convention, held at New York,s ... Save Your Vision Month, sponsored by the American Optometric Association, ... the importance of receiving comprehensive eye exams. In recognition of ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts ... is legal will generate $655 million in taxes on retail sales. ... taxes, such as Washington State,s 37% cannabis ... state sales taxes that are applied on all retail sales. By ...
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
Breaking Medicine Technology:
(Date:3/27/2017)... IL (PRWEB) , ... March 27, 2017 , ... ... systems, recently received the CE Certificate of Conformity for the Smart System® 20/20. ... or exceed the highest industry standards and specifications such as ANSI, ISO and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... 2017 , ... According to the American Cancer Society , the average ... 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, the ... avoid this latter group, tune in to Lifestyle Magazine on April 9, ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/25/2017)... ... , ... Getting earned media coverage meaningful for Garden Media Group's clients is ... year, Garden Media aims to provide material helpful to clients’ goals and bottom lines. ... key messages to gain coveted media placements, Garden Media wows clients year-round. , ...
Breaking Medicine News(10 mins):